Literature DB >> 20384488

Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups.

Guo-Pei Yu1, James Chun-Lun Li, Daniel Branovan, Steven McCormick, Stimson P Schantz.   

Abstract

BACKGROUND: Thyroid cancer incidence has continuously increased for decades and the causes of this increase are still controversial. The objective of this study was to examine if the increased trend is different among the different National Cancer Institute (NCI) Race/Ethnicity Groups (REGs) within the NCI surveillance epidemiology and end results database for the United States.
METHODS: Using recent 13-year surveillance epidemiology and end results data, we described the specific incidence trend of thyroid cancer for the REGs by tumor size, tested the statistical significance of the trend of incidence, and estimated the annual percentage change (APC) and 95% confidence interval. In addition, we compared the difference of 5-year survival rate among the REGs.
RESULTS: Papillary thyroid cancer incidence significantly increased over 13 years from 1992 to 2004 among the five major REGs. The estimated APC was 5.6% (95% confidence interval = 5.1%-6.1%, p < 0.01) for the non-Hispanic whites group, 4.3% (3.0-5.5, p < 0.01) for the Blacks group, 2.8% (1.5-4.2, p < 0.01) for the Hispanic whites group, 1.5% (0.5-2.5, p < 0.01) for the Asians group, and 1.1% (-2.2-4.6, p = 0.477) for the American Indians/Alaska Natives group, respectively. The APCs among the REGs were significantly different (Z = 7.89, p < 0.001). The upward incidence trend could be seen in all small or large tumors as well as in women or in men. The proportion of local staged thyroid cancer increased by 24% in the Blacks group, 14.4% in the Hispanic whites group, 14.3% in the non-Hispanic whites group, and only 4.0% in the Asians group between two periods of 1992-1996 and 2000-2004. Five-year survival rates of patients with papillary tumor were about 95%, but that of anaplastic tumor ranged from 5.6% to 11.4% among REGs.
CONCLUSION: The time trend of incidence of thyroid cancer is different among the different NCI REGs. Differences in diagnostic scrutiny may explain the differences in the REG-related trend, but this cannot easily explain the relatively small degree of increase in the trend in the Asian and the Indians/Alaska Natives groups nor can it explain the increase in the trend of large tumors that are likely to be discovered by self-palpation by patients.

Entities:  

Mesh:

Year:  2010        PMID: 20384488     DOI: 10.1089/thy.2008.0281

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  43 in total

1.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

Review 2.  The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.

Authors:  Ercole Cavalieri; Eleanor Rogan
Journal:  Mol Aspects Med       Date:  2013-08-30

3.  Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006.

Authors:  Briseis Aschebrook-Kilfoy; Mary H Ward; Mona M Sabra; Susan S Devesa
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

4.  Geospatial and Temporal Analysis of Thyroid Cancer Incidence in a Rural Population.

Authors:  John P Hanley; Erin Jackson; Leslie A Morrissey; Donna M Rizzo; Brian L Sprague; Indra Neil Sarkar; Frances E Carr
Journal:  Thyroid       Date:  2015-06-02       Impact factor: 6.568

5.  Benign and Malignant Thyroid Incidentalomas Are Rare in Routine Clinical Practice: A Review of 97,908 Imaging Studies.

Authors:  Abhineet Uppal; Michael G White; Sapna Nagar; Briseis Aschebrook-Kilfoy; Paul J Chang; Peter Angelos; Edwin L Kaplan; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-09       Impact factor: 4.254

6.  Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.

Authors:  Sandya Liyanarachchi; Anna Wojcicka; Wei Li; Malgorzata Czetwertynska; Elzbieta Stachlewska; Rebecca Nagy; Kevin Hoag; Bernard Wen; Rafal Ploski; Matthew D Ringel; Izabella Kozłowicz-Gudzinska; Wojciech Gierlikowski; Krystian Jazdzewski; Huiling He; Albert de la Chapelle
Journal:  Thyroid       Date:  2013-08-29       Impact factor: 6.568

7.  Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells.

Authors:  Raktim Biswas; Phil-Sang Chung; Jeong Hwan Moon; Seung-Ha Lee; Jin-Chul Ahn
Journal:  Lasers Med Sci       Date:  2013-10-10       Impact factor: 3.161

8.  Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.

Authors:  Elaine Cristina Morari; Joyce Rosário Silva; Ana Carolina Trindade Guilhen; Lucas Leite Cunha; Marjory Alana Marcello; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2010-12       Impact factor: 3.943

Review 9.  Thyroidectomy in elderly patients aged ≥70 years.

Authors:  Davide Inversini; Andrea Morlacchi; Giuseppinella Melita; Simona Del Ferraro; Carlo Boeri; Mattia Portinari; Antonino Cancellieri; Francesco Frattini; Antonio Giacomo Rizzo; Gianlorenzo Dionigi
Journal:  Gland Surg       Date:  2017-10

10.  SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.

Authors:  Huiling He; Agnieszka Bronisz; Sandya Liyanarachchi; Rebecca Nagy; Wei Li; Yungui Huang; Keiko Akagi; Motoyasu Saji; Dorota Kula; Anna Wojcicka; Nikhil Sebastian; Bernard Wen; Zbigniew Puch; Michal Kalemba; Elzbieta Stachlewska; Malgorzata Czetwertynska; Joanna Dlugosinska; Kinga Dymecka; Rafal Ploski; Marek Krawczyk; Patrick J Morrison; Matthew D Ringel; Richard T Kloos; Krystian Jazdzewski; David E Symer; Veronica J Vieland; Michael Ostrowski; Barbara Jarząb; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.